One of Sweden's largest and most important ventures in medicine and life science is soon to commence - the building of a brand new center for accelerating Advanced Therapy Medicinal Products (ATMP) to treat diseases that until now could not be cured. GoCo Health Innovation City will establish a laboratory for international research at the forefront of the pharmaceutical industry.
"GoCo Lab gives us the conditions to attract the world's best researchers and talents. It strengthens Sweden as a research nation and enables us to take a leading role in development in the life science area," says Marcus Wallenberg, chairman of Patricia Industries.
There is a global race around Advanced Therapy Medicinal Products (ATMP), medicines and methods based on the body's own cells, tissues or genes. These advanced medicines provide ground-breaking possibilities for the treatment of diseases and injuries, for example Alzheimer's, leukemia and other genetically inherited diseases. Relevant advanced laboratories have long been in short supply in Sweden. The establishment of GoCo Lab provides a large and necessary increase in capacity and infrastructure to create the medicines of the future.
- State-of-the-art lab infrastructure is an extremely important asset for GoCo Health Innovation City as a life science cluster, where the lab will be crucial for health innovations, says Jacob Torell, CEO of Next Step Group and one of the initiators of GoCo Health Innovation City.
Close interaction between business and academia has been one of the keys to success since the start of GoCo Health Innovation City.
- The GoCo Lab will give the University of Gothenburg new opportunities to pursue research and innovation in collaboration with private actors. It is important in order for our outstanding academic research to create societal benefits even faster, says Eva Wiberg, President Gothenburg University.
The largest tenant in the new lab will be CCRM Nordic, a non-profit company that focuses on driving ATMP development forward according to the successful model developed by CCRM in Toronto. The initiative is supported by Vinnova and a consortium of companies such as AstraZeneca, CombiGene, Cytiva, Getinge, Takara Bio Europe, Tataa Biocenter and Verigraft as well as incubator and investor GU Ventures with its association to the University of Gothenburg.
- CCRM Nordic's future capacity will make a significant difference so that new advanced medicines can reach all the way to the patient. I feel privileged to be a part of this, says Fredrik Wessberg, CEO of CCRM Nordic.
Pharmaceutical and biotech company AstraZeneca also moves in to GoCo Lab, a logical step both in terms of research and relationships. The entire GoCo Health Innovation City is set up in close collaboration with AstraZeneca. With the lab in place, the area's infrastructure is further strengthened to be able to develop new innovative therapies for patients.
For more information please contact:
Jacob Torell: jacob.torell@nextstep.se
Fredrik Wessberg: fredrik.wessberg@ccrmnordic.se
Marie Uddenmyr: marie.uddenmyr@goco.se
FACT SHEET
The SEK multi-million investment GoCo Lab is part of the fast-growing life science cluster GoCo Health Innovation City, adjacent to AstraZeneca's facility in Mölndal. GoCo Health Innovation City is planned to become a unique neighborhood for employees and researchers in the global frontline of life science.
With the start of construction of the GoCo Lab, 3 of the total SEK 6 billion investment is now passed, paving the way for new world-leading solutions to health challenges and creating around 8,000 new jobs.
GoCo Health Innovation City has been initiated by the companies Next Step and Vectura Fastigheter with AstraZeneca as development partner. Vectura Fastigheter is a property company within Investor AB. Next Step is an urban developer that is 50% owned by Fastighets AB Balder.
The purpose-built GoCo Lab is built in cooperation with the stakeholders who will use the infrastructure. The building should be up and running in 2026, with operations in temporary premises before then.
CCRM Nordic is established as a new entity with national infrastructure for the development, manufacturing and commercialization of Advanced Therapy Medicinal Products (ATMP), and will be accessible to stakeholders from academia, industry and the healthcare sector.
CCRM Nordic is supported by an industry consortium that helps establish the center as an organization with specialized infrastructure and expertise focused on Advanced Therapy Medicinal Product (ATMP) development.
The consortium consists of large Swedish ATMP organizations such as AstraZeneca, CombiGene, Cytiva, Getinge, Takara Bio Europe, Tataa Biocenter and Verigraft as well as local innovation actors such as GoCo Health Innovation City and GU Ventures.
We use cookies to ensure that we give you the best experience on our website. By continuing to browse the site you are agreeing to our use of cookies. Read more about our data and privacy policy here.
OK